Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eggert Stockfleth

Showing results (91-100 of 198) with videos related to

Pageof 20
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2019
A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With NivolumabThilo Gambichler, Ulrike Schröter, Stefan Höxtermann, et al.
Virology|January 26, 2010
Genomic characterization of a novel human papillomavirus (HPV-117) with a high viral load in a persisting wartAnja Köhler, Marc Gottschling, Jana Förster, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 26, 2024
Actinic keratosis: Current challenges and unanswered questionsJosep Malvehy, Alexander J Stratigos, Martine Bagot, et al.
Plos One|April 17, 2012
Mutual regulation of Bcl-2 proteins independent of the BH3 domain as shown by the BH3-lacking protein Bcl-x(AK)Michael Plötz, Amir M Hossini, Bernhard Gillissen, et al.
Archives of Dermatology|November 20, 2002
A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratosesEggert Stockfleth, Thomas Meyer, Bernd Benninghoff, et al.
Journal of the American Academy of Dermatology|February 6, 2010
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cyclesC William Hanke, Kenneth R Beer, Eggert Stockfleth, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin TypeAgustin Alomar, Eggert Stockfleth, Thomas Dirschka, et al.
Dermatology and Therapy|December 8, 2017
Efficacy and Safety of Three Cryotherapy Devices for Wart Treatment: A Randomized, Controlled, Investigator-Blinded, Comparative StudyImko Walczuk, Frank Eertmans, Bart Rossel, et al.
Clinical, Cosmetic and Investigational Dermatology|February 28, 2020
Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized TrialJohn T Lear, Axel Hauschild, Eggert Stockfleth, et al.
Plos One|November 24, 2011
Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2Dorothea Muschik, Ilona Braspenning-Wesch, Eggert Stockfleth, et al.
Pageof 20

Showing results (91-100 of 198) with videos related to

Sort By:
Pageof 20
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2019
A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With NivolumabThilo Gambichler, Ulrike Schröter, Stefan Höxtermann, et al.
Virology|January 26, 2010
Genomic characterization of a novel human papillomavirus (HPV-117) with a high viral load in a persisting wartAnja Köhler, Marc Gottschling, Jana Förster, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 26, 2024
Actinic keratosis: Current challenges and unanswered questionsJosep Malvehy, Alexander J Stratigos, Martine Bagot, et al.
Plos One|April 17, 2012
Mutual regulation of Bcl-2 proteins independent of the BH3 domain as shown by the BH3-lacking protein Bcl-x(AK)Michael Plötz, Amir M Hossini, Bernhard Gillissen, et al.
Archives of Dermatology|November 20, 2002
A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratosesEggert Stockfleth, Thomas Meyer, Bernd Benninghoff, et al.
Journal of the American Academy of Dermatology|February 6, 2010
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cyclesC William Hanke, Kenneth R Beer, Eggert Stockfleth, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin TypeAgustin Alomar, Eggert Stockfleth, Thomas Dirschka, et al.
Dermatology and Therapy|December 8, 2017
Efficacy and Safety of Three Cryotherapy Devices for Wart Treatment: A Randomized, Controlled, Investigator-Blinded, Comparative StudyImko Walczuk, Frank Eertmans, Bart Rossel, et al.
Clinical, Cosmetic and Investigational Dermatology|February 28, 2020
Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized TrialJohn T Lear, Axel Hauschild, Eggert Stockfleth, et al.
Plos One|November 24, 2011
Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2Dorothea Muschik, Ilona Braspenning-Wesch, Eggert Stockfleth, et al.
Pageof 20